{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:33:12Z","timestamp":1789576392164,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.drup.2026.101411","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T23:09:33Z","timestamp":1778108973000},"page":"101411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Patient-derived ovarian cancer organoids as platforms for predicting platinum resistance and screening tumor stem cell inhibitors"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4917-6130","authenticated-orcid":false,"given":"Mingxia","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhi","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9000-0332","authenticated-orcid":false,"given":"Mingxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglei","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanguang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"D1","key":"10.1016\/j.drup.2026.101411_bib1","doi-asserted-by":"crossref","first-page":"D679","DOI":"10.1093\/nar\/gkad960","article-title":"WikiPathways 2024: next generation pathway database","volume":"52","author":"Agrawal","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drup.2026.101411_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.104490","article-title":"A deep learning model for detection and tracking in high-throughput images of organoid","volume":"134","author":"Bian","year":"2021","journal-title":"Comput. Biol. Med."},{"issue":"17","key":"10.1016\/j.drup.2026.101411_bib3","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"JNCI J. Nat. Cancer Inst."},{"issue":"6","key":"10.1016\/j.drup.2026.101411_bib4","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1021\/acs.jmedchem.6b01825","article-title":"Inhibition of the aldehyde dehydrogenase 1\/2 family by psoralen and coumarin derivatives","volume":"60","author":"Buchman","year":"2017","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.drup.2026.101411_bib5","article-title":"Application of cancer organoids: the forefront of personalized oncology and preclinical testing","volume":"1","author":"Cao","year":"2025","journal-title":"OR"},{"issue":"14","key":"10.1016\/j.drup.2026.101411_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian cancer","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.drup.2026.101411_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s42003-024-05826-1","article-title":"Single-cell transcriptome analysis of epithelial, immune, and stromal signatures and interactions in human ovarian cancer","volume":"7","author":"Chai","year":"2024","journal-title":"Commun. Biol."},{"issue":"8","key":"10.1016\/j.drup.2026.101411_bib8","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/1759-7714.13542","article-title":"Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients","volume":"11","author":"Chen","year":"2020","journal-title":"Thorac. Cancer"},{"issue":"18","key":"10.1016\/j.drup.2026.101411_bib9","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1111\/j.1742-4658.2011.08235.x","article-title":"Multidrug resistance proteins (MRPs\/ABCCs) in cancer chemotherapy and genetic diseases","volume":"278","author":"Chen","year":"2011","journal-title":"FEBS J."},{"issue":"22","key":"10.1016\/j.drup.2026.101411_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202101176","article-title":"Patient-derived organoids can guide personalized-therapies for patients with advanced breast cancer","volume":"8","author":"Chen","year":"2021","journal-title":"Adv. Sci."},{"issue":"2","key":"10.1016\/j.drup.2026.101411_bib11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/cbf.3577","article-title":"Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer","volume":"39","author":"Chen","year":"2021","journal-title":"Cell Biochem. Funct."},{"issue":"51","key":"10.1016\/j.drup.2026.101411_bib12","doi-asserted-by":"crossref","first-page":"20778","DOI":"10.1073\/pnas.1019452108","article-title":"Notch1 regulates the expression of the multidrug resistance gene ABCC1\/MRP1 in cultured cancer cells","volume":"108","author":"Cho","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.drup.2026.101411_bib13","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4143\/crt.2022.1630","article-title":"Establishment of patient-derived organoids using ascitic or pleural fluid from cancer patients","volume":"55","author":"Choi","year":"2023","journal-title":"Cancer Res. Treat."},{"issue":"45","key":"10.1016\/j.drup.2026.101411_bib14","doi-asserted-by":"crossref","first-page":"30880","DOI":"10.1074\/jbc.R114.609248","article-title":"Multidrug resistance protein 1 (MRP1, ABCC1), a \"multitasking\" ATP-binding cassette (ABC) transporter","volume":"289","author":"Cole","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.drup.2026.101411_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/1098-2388(200007\/08)19:1<42::AID-SSU7>3.0.CO;2-M","article-title":"Cytoreductive surgery for advanced stages of ovarian cancer","volume":"19","author":"Dauplat","year":"2000","journal-title":"Semin. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.drup.2026.101411_bib16","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","article-title":"Prospective derivation of a living organoid biobank of colorectal cancer patients","volume":"161","author":"van de Wetering","year":"2015","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.drup.2026.101411_bib17","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202300306R","article-title":"LAMA5 promotes cell proliferation and migration in ovarian cancer by activating Notch signaling pathway","volume":"37","author":"Diao","year":"2023","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.drup.2026.101411_bib18","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1038\/s41467-021-23379-3","article-title":"Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics","volume":"12","author":"Ding","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.drup.2026.101411_bib19","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.amepre.2015.09.023","article-title":"A systematic review of symptoms for the diagnosis of ovarian cancer","volume":"50","author":"Ebell","year":"2016","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.drup.2026.101411_bib20","article-title":"Stem cell markers in neoplasms and their relationship with progression-free and overall survival in patients with recurrence","author":"Eguiluz-Melendez","year":"2024","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.drup.2026.101411_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.drup.2026.101411_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050630","article-title":"Tumour-derived laminin \u03b15 (LAMA5) promotes colorectal liver metastasis growth, branching angiogenesis and notch pathway inhibition","volume":"11","author":"Gordon-Weeks","year":"2019","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.drup.2026.101411_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9081021","article-title":"Utilizing patient-derived epithelial ovarian cancer tumor organoids to predict carboplatin resistance","volume":"9","author":"Gorski","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.drup.2026.101411_bib24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12967-023-04094-7","article-title":"Single-cell transcriptomics in ovarian cancer identify a metastasis-associated cell cluster overexpressed RAB13","volume":"21","author":"Guo","year":"2023","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.drup.2026.101411_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.500","article-title":"Single-cell transcriptomes reveal heterogeneity of high-grade serous ovarian carcinoma","volume":"11","author":"Hao","year":"2021","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.drup.2026.101411_bib26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12905-021-01260-1","article-title":"Women's cancers in China: a spatio-temporal epidemiology analysis","volume":"21","author":"He","year":"2021","journal-title":"BMC Womens Health"},{"issue":"11","key":"10.1016\/j.drup.2026.101411_bib27","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","article-title":"Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids","volume":"8","author":"Hill","year":"2018","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.drup.2026.101411_bib28","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019104013","article-title":"Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment","volume":"39","author":"Hoffmann","year":"2020","journal-title":"EMBO J."},{"issue":"4","key":"10.1016\/j.drup.2026.101411_bib29","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2478\/jtim-2024-0025","article-title":"Actin-related protein 2\/3 complex subunit 1B promotes ovarian cancer progression by regulating the AKT\/PI3K\/mTOR signaling pathway","volume":"12","author":"Ke","year":"2024","journal-title":"J. Transl. Int. Med."},{"issue":"9990","key":"10.1016\/j.drup.2026.101411_bib30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.drup.2026.101411_bib31","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/pr.111.005538","article-title":"Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application","volume":"64","author":"Koppaka","year":"2012","journal-title":"Pharmacol. Rev."},{"issue":"5","key":"10.1016\/j.drup.2026.101411_bib32","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","article-title":"An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity","volume":"25","author":"Kopper","year":"2019","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.drup.2026.101411_bib33","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","article-title":"An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity","volume":"25","author":"Kopper","year":"2019","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.drup.2026.101411_bib34","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/ijgc-2022-003806","article-title":"Primary mucinous ovarian cancer: options for surgery and chemotherapy","volume":"32","author":"Kurnit","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6","key":"10.1016\/j.drup.2026.101411_bib35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1593\/neo.09112","article-title":"Inflammatory cytokine tumor necrosis factor \u03b1 confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells","volume":"11","author":"Kwong","year":"2009","journal-title":"Neoplasia"},{"issue":"20","key":"10.1016\/j.drup.2026.101411_bib36","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1038\/s41388-021-01790-w","article-title":"Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity","volume":"40","author":"Lei","year":"2021","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.drup.2026.101411_bib37","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdy009","article-title":"Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy","volume":"29","author":"Li","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"4","key":"10.1016\/j.drup.2026.101411_bib38","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s11427-022-2239-y","article-title":"PanGu drug model: learn a molecule like a human","volume":"66","author":"Lin","year":"2023","journal-title":"Sci. China Life Sci."},{"issue":"5","key":"10.1016\/j.drup.2026.101411_bib39","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41418-022-00943-y","article-title":"p53 in ferroptosis regulation: the new weapon for the old guardian","volume":"29","author":"Liu","year":"2022","journal-title":"Cell Death Differ."},{"issue":"23","key":"10.1016\/j.drup.2026.101411_bib40","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1158\/0008-5472.CAN-21-1337","article-title":"ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression","volume":"81","author":"Liu","year":"2021","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.drup.2026.101411_bib41","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1002\/cam4.1485","article-title":"LGR5 promotes epithelial ovarian cancer proliferation, metastasis, and epithelial-mesenchymal transition through the Notch1 signaling pathway","volume":"7","author":"Liu","year":"2018","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.drup.2026.101411_bib42","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.stemcr.2020.03.004","article-title":"Developing organoids from ovarian cancer as experimental and preclinical models","volume":"14","author":"Maenhoudt","year":"2020","journal-title":"Stem Cell Rep."},{"issue":"13","key":"10.1016\/j.drup.2026.101411_bib43","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMra1813254","article-title":"Mucinous ovarian carcinoma","volume":"380","author":"Morice","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.drup.2026.101411_bib44","first-page":"234","article-title":"New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools","volume":"38","author":"Mu\u00f1oz-Galv\u00e1n","year":"2019","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"issue":"1","key":"10.1016\/j.drup.2026.101411_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69488-9","article-title":"Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing","volume":"10","author":"Nanki","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.drup.2026.101411_bib46","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/jjco\/hym145","article-title":"Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602","volume":"38","author":"Onda","year":"2008","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"513","key":"10.1016\/j.drup.2026.101411_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay2574","article-title":"Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients","volume":"11","author":"Ooft","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"17","key":"10.1016\/j.drup.2026.101411_bib48","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.drup.2026.101411_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090371","article-title":"An mDia2\/ROCK signaling axis regulates invasive egress from epithelial ovarian cancer spheroids","volume":"9","author":"Pettee","year":"2014","journal-title":"PLoS One"},{"issue":"1-2","key":"10.1016\/j.drup.2026.101411_bib50","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A living biobank of breast cancer organoids captures disease heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.drup.2026.101411_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45297-8","article-title":"Systematic review: predictive value of organoids in colorectal cancer","volume":"13","author":"Sakshaug","year":"2023","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.drup.2026.101411_bib52","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.devcel.2023.04.012","article-title":"A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids","volume":"58","author":"Senkowski","year":"2023","journal-title":"Dev. Cell"},{"issue":"2","key":"10.1016\/j.drup.2026.101411_bib53","article-title":"Genetically defined, syngeneic organoid platform for developing combination therapies for ovarian cancer","volume":"11","author":"Shuang","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101411_bib54","article-title":"Patents on PARP-1 Inhibitors for the Management of Cancer from 2017-2023","author":"Singh","year":"2024","journal-title":"Recent Pat. Anticancer Drug Discov."},{"issue":"W1","key":"10.1016\/j.drup.2026.101411_bib55","doi-asserted-by":"crossref","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drup.2026.101411_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106232","article-title":"Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer","volume":"179","author":"Tao","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drup.2026.101411_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101028","article-title":"Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor","volume":"73","author":"Teng","year":"2024","journal-title":"Drug Resist. Update"},{"issue":"10","key":"10.1016\/j.drup.2026.101411_bib58","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"6378","key":"10.1016\/j.drup.2026.101411_bib59","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.drup.2026.101411_bib60","article-title":"Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study","volume":"4","author":"Wang","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"11","key":"10.1016\/j.drup.2026.101411_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107762","article-title":"Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responses","volume":"31","author":"de Witte","year":"2020","journal-title":"Cell Rep."},{"issue":"12","key":"10.1016\/j.drup.2026.101411_bib62","article-title":"A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids","volume":"58","author":"Wojciech","year":"2023","journal-title":"Dev. Cell"},{"key":"10.1016\/j.drup.2026.101411_bib63","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8607859","article-title":"UBE2C induces cisplatin resistance via ZEB1\/2-dependent upregulation of ABCG2 and ERCC1 in NSCLC cells","volume":"2019","author":"Wu","year":"2019","journal-title":"J. Oncol."},{"issue":"24","key":"10.1016\/j.drup.2026.101411_bib64","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.21037\/atm-20-7408","article-title":"The landscape of kinase domain duplication in Chinese lung cancer patients","volume":"8","author":"Wu","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.drup.2026.101411_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101151","article-title":"CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancer","volume":"77","author":"Xue","year":"2024","journal-title":"Drug Resist. Update"},{"issue":"11","key":"10.1016\/j.drup.2026.101411_bib66","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1021\/acs.jmedchem.8b00270","article-title":"Discovery of orally bioavailable, quinoline-based aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with potent cellular activity","volume":"61","author":"Yang","year":"2018","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.drup.2026.101411_bib67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","article-title":"Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer","volume":"26","author":"Yao","year":"2020","journal-title":"Cell Stem Cell"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T03:35:30Z","timestamp":1781062530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626000622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":67,"alternative-id":["S1368764626000622"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101411","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-derived ovarian cancer organoids as platforms for predicting platinum resistance and screening tumor stem cell inhibitors","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101411"}}